Barclays
NERV icon

Barclays’s Minerva Neurosciences NERV Stock Holding History

Barclays’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.9K Buy
6,826
+6,680
+4,575% +$36.2K ﹤0.01% 4406
2026
Q1 		$880 Buy
+146
New +$838 ﹤0.01% 4905
2025
Q4 		– Sell
-1
Closed -$2 – 5537
2025
Q3 		$2 Buy
+1
New +$2 ﹤0.01% 5436
2024
Q4 		– Sell
-3
Closed -$8 – 5404
2024
Q3 		$8 Buy
+3
New +$9 ﹤0.01% 5244
2022
Q3 		– Sell
-8,430
Closed -$28K – 5024
2022
Q2 		$28K Buy
+8,430
New +$34.4K ﹤0.01% 4272
2021
Q4 		– Sell
-631
Closed -$9K – 4541
2021
Q3 		$9K Sell
631
-1,752
-74% -$26.4K ﹤0.01% 4535
2021
Q2 		$44K Sell
2,383
-1,333
-36% -$28.7K ﹤0.01% 4191
2021
Q1 		$86K Buy
3,716
+1,273
+52% +$31.8K ﹤0.01% 4065
2020
Q4 		$45K Sell
2,443
-527
-18% -$13.3K ﹤0.01% 4451
2020
Q3 		$76K Sell
2,970
-286
-9% -$7.73K ﹤0.01% 4388
2020
Q2 		$94K Sell
3,256
-4,287
-57% -$251K ﹤0.01% 4563
2020
Q1 		$363K Sell
7,543
-5,299
-41% -$320K ﹤0.01% 3838
2019
Q4 		$730K Buy
12,842
+10,929
+571% +$482K ﹤0.01% 3950
2019
Q3 		$119K Sell
1,913
-474
-20% -$26.8K ﹤0.01% 5353
2019
Q2 		$107K Buy
2,387
+1,075
+82% +$53.8K ﹤0.01% 5642
2019
Q1 		$83K Buy
1,312
+892
+212% +$53.6K ﹤0.01% 5505
2018
Q4 		$22K Sell
420
-1,036
-71% -$75.8K ﹤0.01% 5853
2018
Q3 		$146K Buy
1,456
+1,167
+404% +$87.7K ﹤0.01% 5243
2018
Q2 		$20K Sell
289
-491
-63% -$29.8K ﹤0.01% 6192
2018
Q1 		$39K Buy
780
+39
+5% +$1.87K ﹤0.01% 6083
2017
Q4 		$35K Buy
741
+656
+772% +$32.5K ﹤0.01% 5971
2017
Q3 		$5K Sell
85
-117
-58% -$6.71K ﹤0.01% 6418
2017
Q2 		$15K Buy
202
+41
+25% +$2.65K ﹤0.01% 5918
2017
Q1 		$11K Sell
161
-485
-75% -$37.7K ﹤0.01% 6051
2016
Q4 		$61K Buy
+646
New +$65.9K ﹤0.01% 5038
2016
Q3 		– Hold
0
– – – 6727

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's NERV Position: Q2 2026 in Review

Barclays increased its Minerva Neurosciences (NERV) stake by 4,575% in Q2 2026, buying an estimated $36.2K and bringing the position to 6,826 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4406.

Barclays first reported a position in NERV in Q4 2016 and has held it in 25 quarters since. The position peaked at $730K in Q4 2019. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Barclays held 6,826 shares of Minerva Neurosciences worth $37.9K as of Q2 2026.
  • Barclays bought 6,680 Minerva Neurosciences shares in Q2 2026, an estimated $36.2K.
  • Minerva Neurosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4406 holding.
  • Barclays first reported a position in Minerva Neurosciences in Q4 2016 and has held it in 25 quarters since.
  • Barclays's Minerva Neurosciences position peaked at $730K in Q4 2019.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.